CrossAssetDataThe Company File
···
MXCT

MaxCyte, Inc.

MaxCyte, Inc. is classed by the SEC under Services-Commercial Physical & Biological Research (industry code 8731), based in Rockville, MD. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $21 million and a loss of $45 million (its filed statements).

Pre-revenue company Services-Commercial Physical & Biological Research Rockville, MD filings since 2004 8 of 9 filed, 1 estimated
Ask the desk about MXCT → Compare MXCT with ABSI → Price chart on TradingView ↗ Full EDGAR file ↗ Watch MXCT →

Sector peers: ABSIOABINRCBIAF

4.0/10headline grade
vs its business-model standard
3.4/10past 4.6/10present 4.0/10future

Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 8731), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.

The grade, in three tenses

Headline 4.0 out of ten, 8 of 9 metrics filed and 1 estimated: past 3.4 out of ten, present 4.6 out of ten, future 4.0 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.

The nine metrics

  • Surviving crises (past): 3.3 out of ten. 2 warning events since 2017; the latest 2026-06-16. 33rd percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Track record (past): 3.9 out of ten. +7.3% a year over 7 filed years; profitable in 0 of 7. 39th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Shareholder treatment (past): 2.9 out of ten. CrossAssetData estimate 2.9/10, confidence 35 of 100 (one part). 29th percentile among 12 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
  • Financial health (present): 5.5 out of ten. ROE -26%: lost 26¢ per shareholder dollar. Leverage 15%: owes 15¢ per asset dollar. 55th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Industry position (present): 4.0 out of ten. bottom 40% of 12 in its family; net margin -135.1%. 40th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Leadership (present): 3.6 out of ten. bottom 36% of 8 in its family for leadership; chief executive since 2024. 36th percentile among 8 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
  • Room to expand (future): 5.1 out of ten. top 49% of 12 in its family for room to expand. 51st percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Growth drivers (future): 3.6 out of ten. bottom 36% of 12 in its family for growth drivers. 36th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
  • Expectations vs reality (future): 3.2 out of ten. bottom 32% of 11 in its family for expectations against reality. 32nd percentile among 11 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).

The filing record

Newest annual report: Form 10-K filed 2026-03-25 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-13 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-12 (on EDGAR). Newest filing: Form 10-Q, 2026-08-13. Filings on record since 2004. Read from EDGAR 2026-10-12.

Where the revenue comes from

Product and service lines in fiscal 2025: Product 57%, License 38%, Assay and Other Service Revenue 6%. By geography: United States 64%, Outside the United States 36%. As tagged in its annual report (Form 10-K, filed 2026-03-25).

Who runs it

Masoud, Maher (President and CEO); Ahuja, Parmeet (Chief Financial Officer); Swirsky, Douglas J (CHIEF FINANCIAL OFFICER); Al-Wakeel, Yasir B. (director); Balthrop, Patrick J (director); Brooke, William W (director); Collins, Cynthia (director); Douglas, Richard (director); Erck, Stanley C (director); Hemrajani, Rekha (director); and 1 more. 11 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.

This file: Overview · Past · Present · Future · Filings · every company on file

Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.